SCHEMBL2235409

SCHEMBL2235409

CCN1CCN(Cc2ccc(Nc3ncnc4c(C(=O)Nc5c(Cl)c(OC)cc(OC)c5Cl)csc34)cc2C(F)(F)F)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K7 O43318 7/20 0.49
MAP4K2 Q12851 7/20 0.49
FES P07332 4/20 0.49
FER P16591 4/20 0.49
HCK P08631 10/20 0.46
NR2C2 P49116 10/20 0.46
GCK P35557 3/20 0.46
MAPK14 Q16539 6/20 0.46
BTK Q06187 1/20 0.45
MAP3K20 Q9NYL2 3/20 0.45
MKNK2 Q9HBH9 2/20 0.44
STK25 O00506 1/20 0.44
CIT O14578 1/20 0.44
MAP2K7 O14733 1/20 0.44
IKBKB O14920 1/20 0.44
AURKA O14965 1/20 0.44
GAK O14976 1/20 0.44
CHUK O15111 1/20 0.44
MUSK O15146 1/20 0.44
MAPK13 O15264 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14125163 0.97 MAP3K7 (0.51) MAP3K7MAP4K2FESFERHCK
SCHEMBL2233536 0.91 MAP3K7 (0.45) MAP3K7MAP4K2FESFERHCK
SCHEMBL14125158 0.89 MAP3K7 (0.44) MAP3K7MAP4K2FESFERHCK
SCHEMBL2235986 0.89 FGFR3 (0.48) JAK2ABL1RAF1INSRLCK
SCHEMBL2232217 0.85 FGFR3 (0.58) JAK2ABL1EGFRINSRLCK
SCHEMBL2234120 0.84 FGFR1 (0.47) MAP3K7JAK2ABL1EGFRRAF1
SCHEMBL2233010 0.83 FGFR3 (0.56) JAK2ABL1EGFRRAF1INSR
SCHEMBL2231880 0.82 FGFR3 (0.45) AURKAJAK2ABL1EGFRRAF1
SCHEMBL2233532 0.82 FGFR1 (0.47) JAK2ABL1INSRLCKFYN
SCHEMBL2234937 0.82 FGFR3 (0.53) JAK2ABL1INSRLCKFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3141552-B1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM IND CO LTD (KR) 2019-04-17 EP claimed
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase HANMI PHARM. CO., LTD. (KR) 2018-10-30 US claimed
EP-3141552-A1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2017-03-15 EP claimed
EP-2528920-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2012-12-05 EP claimed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US claimed
WO-2011093672-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM. CO., LTD. (KR) 2011-08-04 WO claimed
EP-3141552-B1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM IND CO LTD (KR) 2019-04-17 EP disclosed
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase HANMI PHARM. CO., LTD. (KR) 2018-10-30 US disclosed
EP-3141552-A1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2017-03-15 EP disclosed
EP-2528920-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2012-12-05 EP disclosed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US disclosed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US disclosed
WO-2011093672-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM. CO., LTD. (KR) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE CDK2, SBK3, CDK2AP1 MAP3K7 17/4885MAP4K2 55/4885FES 1029/4885
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase CDK2, SBK3, CDK2AP1 MAP3K7 17/4885MAP4K2 55/4885FES 1029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.